12:00 AM
Mar 27, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Status

FMdC: Began Phase I/II trial

Matrix Pharmaceutical Inc. (MATX), Fremont, Calif.
Product: FMdC
Business: Cancer
Therapeutic category: Cell proliferation
Target: Ribonucleotide reductase

Read the full 80 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >